Dates: June 6-7, 2023 | CAR T Cell Therapy and Advances in Cellular Engineering

Researchers in the U.S. recently shed much needed light on the molecular mechanisms underpinning T cell exhaustion, revealing an epigenetic regulator...

In this update, we summarise the two ongoing gene-editing clinical trials for renal cell carcinoma, which is the most common form of kidney cancer...

This week's update features Iovance Biotherapeutics' new cancer immunotherapy candidate IOV-4001 that was recently cleared for clinical trial...

Intellia Therapeutics recently announced that the first patient had been dosed in its Phase 1/2a CRISPR trial for acute myleoid leukaemia (AML). The...

In our first clinical update of 2022, we look at three new IND approvals for gene-edited therapies for life-threatening E. coli infections,...

In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...

In this piece, we provide selected highlights from the 63rd American Society of Hematology annual meeting, held from December 11-14th 2021.